TheSTAT3is often dysregulated in genitourinary tumors. In prostate cancer,STAT3activation correlates with Gleason score and pathological stage and modulates cancer stem cells and epithelial-mesenchymal transition. In addition,STAT3promotes the progression from carcinomain situto invasive bladder cancer and modulates renal cell carcinoma angiogenesis by increasing the expression of HIF1α and VEGF.STAT3is also involved in the response to tyrosine kinase inhibitors sunitinib and axitinib, in patients with metastatic renal cell carcinoma, and to second-generation androgen receptor inhibitor enzalutamide in patients with advanced prostate cancer. In this review, we describe the role ofSTAT3in genitourinary tumors, thus describing its potential for future therapeutic strategies.
Role of STAT3 pathway in genitourinary tumors
PIVA, FRANCESCO;Ciccarese, Chiara;Tortora, Giampaolo;
2015-01-01
Abstract
TheSTAT3is often dysregulated in genitourinary tumors. In prostate cancer,STAT3activation correlates with Gleason score and pathological stage and modulates cancer stem cells and epithelial-mesenchymal transition. In addition,STAT3promotes the progression from carcinomain situto invasive bladder cancer and modulates renal cell carcinoma angiogenesis by increasing the expression of HIF1α and VEGF.STAT3is also involved in the response to tyrosine kinase inhibitors sunitinib and axitinib, in patients with metastatic renal cell carcinoma, and to second-generation androgen receptor inhibitor enzalutamide in patients with advanced prostate cancer. In this review, we describe the role ofSTAT3in genitourinary tumors, thus describing its potential for future therapeutic strategies.
| File | Dimensione | Formato | |
|---|---|---|---|
|
fso-01-15.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
1.36 MB
Formato
Adobe PDF
|
1.36 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
